Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Researchers at WEHI and the Burnet Institute have mapped the human immune response to Plasmodium vivax, revealing how antibodies neutralize the parasite. The study, published in Immunity, shows that protective immunity depends on antibody function and simultaneous targeting of multiple parasite proteins. This insight provides a concrete blueprint for the first effective P. vivax vaccine, a species that accounts for most malaria cases outside Africa. The findings could reshape global malaria‑control strategies by addressing the long‑standing gap left by falciparum‑focused vaccines.
HUTCHMED has launched a first‑in‑human Phase I/IIa trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in the United States and China. The multi‑centre, open‑label study will evaluate safety, tolerability, immunogenicity, pharmacokinetics and early efficacy across dose‑escalation and expansion cohorts. HMPL‑A580...
Affinia Therapeutics announced that the FDA has granted fast‑track designation to its gene‑therapy candidate AFTX‑201 for BAG3‑associated dilated cardiomyopathy. The one‑time intravenous treatment delivers a full‑length BAG3 transgene via an engineered capsid that requires doses five to ten times lower...
Researchers repurposed the FAP inhibitor SP‑13786 as a co‑assembly excipient to create SP co‑assembled nanoparticles (SCAN) that encapsulate hydrophobic drugs. Using molecular dynamics and a random‑forest machine‑learning model, they identified 228 physicochemical descriptors that predict successful nano‑co‑assembly, highlighting aromaticity and...
A BioSpace LinkedIn poll of 1,267 biopharma professionals revealed that 51% would consider returning to the employer that laid them off. Tight labor markets, limited local opportunities, and the appeal of consulting contracts drive this willingness. Respondents cite generous severance...
Researchers at Heidelberg University have engineered modular, heat‑responsive protein switches that function within the narrow 37 °C‑40 °C physiological window. By integrating a plant‑derived sensory domain into diverse proteins, they created allosteric thermoswitches capable of rapid, reversible activation. The technology was validated...
Gilead Sciences is in talks with the South African government to issue a voluntary licence for the local manufacture of lenacapavir, a novel HIV‑prevention drug. The agreement would enable South African firms, identified with help from Unitaid and the US...
Moderna agreed to a roughly $2.25 billion settlement with Genevant Sciences and Arbutus Biopharma, ending disputes over lipid nanoparticle (LNP) technology used in its COVID‑19 vaccine. The deal requires $950 million payable in July 2026 and an additional $1.3 billion contingent on an appellate...
Researchers have generated five single‑cell atlases of human brains affected by Down syndrome, providing unprecedented cell‑type and temporal resolution. The atlases pinpoint molecular signatures that correspond to distinct neuronal and glial populations across developmental stages. By integrating these data, scientists...
Researchers have unveiled a novel HIV‑cure strategy that forces dormant virus particles to reveal themselves to the body’s innate immune system. The method employs a STING‑pathway agonist to coax latent proviruses into producing viral RNA, which then triggers a potent...
The FDA released a draft Level 1 guidance titled “New Clinical Investigation Exclusivity (3‑Year Exclusivity) for Drug Products: Questions and Answers.” The document clarifies statutory and regulatory criteria for obtaining three‑year market exclusivity on new drug applications or supplements. It outlines...
Researchers at the Institute of Science Tokyo directly traced small extracellular vesicles (sEVs) from tumors to urine in mouse models of brain, lung and pancreatic cancer. Using engineered RNA tracers and luminescent‑fluorescent reporters, they showed tumor‑derived sEVs appear in urine...
TriSalus Life Sciences reported Q3 2025 revenue of $11.6 million, a 57% year‑over‑year increase, while adjusted EBITDA loss narrowed to $5.4 million despite one‑time study charges. Gross margin slipped to 84% as new product launches strained manufacturing efficiency, but cash burn improved,...
Atea Pharmaceuticals reported a $329.3 million cash position that funds its Phase III hepatitis C program through 2027 and supports a new hepatitis E pipeline. The CBEYOND and C FORWARD trials are on track, with enrollment completing next month and mid‑2026 respectively, and top‑line data...
Compugen Ltd. reported a dramatic financial turnaround in its Q4 2025 earnings, posting a $56.8 million quarterly profit and $35.3 million annual profit after a year of losses. A $65 million upfront royalty monetization from AstraZeneca boosted cash to $145.6 million, extending the cash runway...
Researchers demonstrated that oral sodium butyrate supplementation prevents amyloid‑β accumulation and neuroinflammation in both the gut and brain of the SAMP8 mouse model of sporadic Alzheimer’s disease. Longitudinal analyses revealed early Aβ deposition in the enteric nervous system, leading to...
Regenxbio reported that enrollment for its Duchenne gene therapy RGX-202 was completed ahead of guidance, with top‑line data slated for early Q2 2026 and a BLA submission planned for mid‑2026. The company confirmed manufacturing capacity of 2,500 annual doses and highlighted...
Scientists engineered a programmable microbial assembly line that transforms PET plastic waste into pyruvate, a universal metabolic feedstock, which downstream microbes then convert into a range of valuable products such as dyes, biopolymers, fuels and electricity. The core bacterium, Pseudomonas...
Preliminary trials of Zorevunersen, an experimental therapy for Dravet syndrome, showed it is safe and well tolerated in 81 children. A single 70 mg dose reduced seizures by about 50%, and three doses cut seizures roughly 80% compared with baseline. The...
University of Michigan researchers discovered that physiological glucose levels sustain aberrant STAT3 activation in colorectal cancer cells, driving tumor proliferation. The study identified glycosylated secreted proteins as mediators of this glucose‑dependent STAT3 signaling, a mechanism also observed in pancreatic, liver,...
The FDA has eliminated risk evaluation and mitigation strategy (REMS) requirements for embryofetal toxicity (EFT) across all endothelin receptor antagonist (ERA) medicines, concluding that labeling alone sufficiently communicates the risk. The change, effective April 2025, applies to ambrisentan, macitentan‑containing products, and...
A March 4, 2026 roundup from Bioengineer highlights a series of biotech breakthroughs. Researchers showed that plant DCL4 outcompetes DCL2, boosting RNA‑silencing efficiency, while short‑term antibacterial coatings were found to lose potency over time. Evo 2’s AI platform now models genetic code across...
MYQORZO (aficamten), a cardiac myosin inhibitor, received FDA approval on Dec 19 2025 for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Approval is based on the SEQUOIA‑HCM phase III trial, a randomized, double‑blind, placebo‑controlled study of 282 patients across 14 countries. At 24 weeks,...
Researchers have identified the Orai1 calcium channel as a pivotal regulator of intracellular Ca2+ signals that govern erythropoiesis. Genetic ablation of Orai1 in mouse models leads to impaired red‑cell maturation and anemia, while pharmacologic activation rescues normal blood counts. The...
ARPA‑H is committing up to $144 million to healthspan‑focused human trials through its PROSPR program, funding seven teams to develop early biomarkers and surrogate endpoints for aging interventions. The agency has awarded Cambrian Bio $30.8 million for an oral rapamycin analog targeting...
The Valeda photobiomodulation system received FDA authorization in November 2024 and has been used clinically since summer 2025 to treat retinal aging. A modest 148‑eye, two‑year study showed statistically significant gains in best‑corrected visual acuity and a lower rate of progression to...
Syantra, a Calgary‑based biotech, is preparing to launch Onco‑ID, a breast‑cancer blood test that detects the body’s immune response rather than circulating tumor DNA. Using machine‑learning analysis of gene‑expression biomarkers, the test aims to identify cancer earlier than mammography and...
Genelux Corporation’s President and CEO Thomas Zindrick discussed the company’s oncolytic virotherapy programs targeting ovarian cancer and non‑small cell lung cancer on the Xtalks Life Science Podcast. The interview highlighted the therapeutic potential of engineered viruses to stimulate anti‑tumor immunity...
The FDA is reportedly reconsidering its stance on peptide compounds, a shift potentially driven by officials linked to Robert F. Kennedy Jr., which could broaden research and bio‑hacking applications. Meanwhile, ivermectin has re‑entered public discourse after high‑profile media mentions, prompting...
Now that is cool. Would love to see more people just trying to design crazy new proteins for non-drug applications like this. Protein design is wildly better / more accessible than it was just a few years ago...
Best evidence yet that GLP-1 drugs reduce the risk of substance abuse, from >600,00 US Veterans across alcohol, nicotine, opioid, cocaine, cannabis @bmj_latest @zalaly @Miao_Cai_SLU https://t.co/rcqUt0kY77
University of Missouri researchers have demonstrated a technique to rewrite data stored in DNA, overcoming the long‑standing limitation that DNA‑encoded information was immutable. The method pairs a compact electronic module with a nanopore sensor, translating electrical signals into binary bits....
We've used a blood test—cell free DNA—for detecting cancer or prenatal fetal abnormalities. It turns out it can be used to detect liver diseases and all-cause mortality from other conditions @ScienceTM https://t.co/IJxPMq7hGU
The Mara Blue initiative has launched a feasibility study for Ireland’s first full‑scale marine biorefinery on Dinish Island near Castletownbere. Led by Munster Technological University in partnership with Pure Ocean Algae and the Castletownbere Fishermen’s Co‑op, the study is co‑funded...
When your "normal" abdominal CT tells you about the 5-year future risks that can't be seen by radiologists, but can by AI (Merlin) https://t.co/DemC983uKz https://t.co/9jqZyVTD3p
$CTMX, +660% in 12 months, approaches its masked ADC catalyst. Via @ApexOnco -> https://t.co/oQI1iQiV4N ( $JANX -58% in the same timeframe)
Evo 2, an AI foundation model published in Nature, was trained on over 9.3 trillion nucleotides from 128 000 genomes spanning bacteria to humans. The model can pinpoint disease‑causing mutations, such as BRCA1 variants, with more than 90 % accuracy and design synthetic genomes...
It got me at "across all domains of life" Predicting pathogenicity of non-coding regions, produces sequences at genome scale, and much more Evo 2, open-source, @Nature today @arcinstitute @pdhsu @BrianHie https://t.co/9CZWmPFhjd
I get asked a lot how Autonomous Labs are different than traditional lab automation, here’s how 👇 Happy to take Qs in comments too https://t.co/AdGMiQWHHT
Antengene and UCB have signed a global license agreement to develop ATG‑201, a CD19/CD3 bispecific T‑cell engager targeting B‑cell‑driven autoimmune diseases. The deal delivers an $80 million upfront payment and unlocks more than $1.1 billion in development and commercial milestones, plus tiered...
The FDA’s Oncologic Drugs Advisory Committee will meet virtually on October 5, 2023 to evaluate Amgen’s supplemental NDA for LUMAKRAS (sotorasib) in KRAS G12C‑mutated non‑small cell lung cancer. The committee will review data from the confirmatory CodeBreaK 200 trial, which could convert the existing...
The FDA has posted a public list of disease areas where external organizations have submitted letters of intent for future Externally‑Led Patient‑Focused Drug Development (EL‑PFDD) meetings. Ten topics ranging from infertility to rare neurological disorders are scheduled between March and...
The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted major HIV research breakthroughs while underscoring persistent funding shortfalls. Experts praised advances in antiretroviral therapy, emerging adjunct treatments, and global advocacy, yet warned that reduced U.S. support could limit access...
Teva Pharmaceuticals has secured a $400 million strategic growth capital agreement with Blackstone Life Sciences to fund the Phase III development of duvakitug, a TL1A‑targeting monoclonal antibody for ulcerative colitis and Crohn’s disease. The four‑year deal grants Blackstone milestone payments and low‑single‑digit...
Batch effects once caused 162 patients to be misclassified. 28 of them received incorrect or unnecessary chemotherapy. The culprit? Contaminated RNA extraction that introduced technical artifacts into the data. https://t.co/WBBFKgvzVC
Scientists at Scripps Research have engineered a native‑like, stabilized version of the hepatitis C virus E1E2 glycoprotein complex and displayed it on self‑assembling protein nanoparticles (SApNPs). The nanoparticle vaccine candidate elicited strong, virus‑specific antibody responses in animal models. This breakthrough overcomes...
Cancer blood tests for screening? Not the way they've been studied to date (age 50+) A new feature @Nature “I’m confident we’re going to see more accurate tests going forward. In high-risk groups, such as those with a genetic predisposition,...
Five interdisciplinary teams will receive up to £20 million each from the UK‑US Cancer Grand Challenges, adding £100 million to the programme and raising total investment to £465 million since 2016. The five projects, spanning 34 institutions in nine countries, target unconventional angles...
Why I think your single-cell cell annotation benchmarking is missing the mark 👇 You trained your model on large of number of cells (millions), and you use your model to annotate a new dataset. https://t.co/GHpQkfLtOE
The FDA issued a complete‑response letter to UniQure, requiring a randomized, double‑blind, sham‑surgery Phase 3 trial for its Huntington’s disease gene therapy, and similarly rejected REGENXBIO’s Hunter syndrome candidate over study design flaws. Regulatory experts warned that the agency’s decision‑making appears...
